{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:50:52Z","timestamp":1772117452609,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003617","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000}}],"reference-count":232,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003617.pub2","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T08:33:57Z","timestamp":1359448437000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C"],"prefix":"10.1002","volume":"2013","author":[{"given":"Ronald L","family":"Koretz","sequence":"first","affiliation":[{"name":"16847 Colven Road Granada Hills CA USA CA 91344"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pleguezuelo","sequence":"additional","affiliation":[{"name":"Reina Sofia University Hospital; Department of Hepatology; Menendez Pidal s\/n Cordoba Spain 14004"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Arvaniti","sequence":"additional","affiliation":[{"name":"Royal Free Hampstead NHS Foundation Trust; Department of Liver Transplantation and Hepatobiliary Medicine; Pond Street Hampstead London UK NW3 2QG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Barrera Baena","sequence":"additional","affiliation":[{"name":"Reina Sofia University Hospital; Department of Gastroenterology and Hepatology; Cordoba Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Ciria","sequence":"additional","affiliation":[{"name":"Reina Sofia University Hospital; Department of Surgery; Cordoba Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurinchi Selvan","family":"Gurusamy","sequence":"additional","affiliation":[{"name":"Royal Free Campus, UCL Medical School; Department of Surgery; Royal Free Hospital, Pond Street London UK NW3 2QG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R","family":"Davidson","sequence":"additional","affiliation":[{"name":"Royal Free Campus, UCL Medical School; Department of Surgery; Royal Free Hospital, Pond Street London UK NW3 2QG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew K","family":"Burroughs","sequence":"additional","affiliation":[{"name":"Royal Free Hampstead NHS Foundation Trust; Sheila Sherlock Liver Centre; Pond Street Hampstead London UK NW3 2QG"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"10.1002\/14651858.CD003617.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0168-8278(01)00110-6","article-title":"Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial","volume":"35","author":"Alric","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2893.1995.tb00022.x","article-title":"Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha","volume":"2","author":"Bresci","year":"1995","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"10.1002\/14651858.CD003617.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1053\/j.gastro.2011.03.010","article-title":"Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C","volume":"140","author":"Bruix","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0004|cit4","first-page":"A798","article-title":"Final results of the EPIC3 cirrhosis maintenance trial: pegintron maintenance therapy in cirrhotic (METAVIR F4) HCV patients, who failed to respond to interferon\/ribavirin (IR) therapy","volume":"136 Suppl 1","author":"Bruix","year":"2009","journal-title":"Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003617.pub2-BIB0005|cit5","first-page":"711A","article-title":"Impact of peginterferon maintenance therapy on biomarkers (Fibrotest [FT]-Acitest [AT]) in cirrhotic (METAVIR F4) HCV prior non-responders. Results from the EPIC3 cirrhosis maintenance trial","volume":"50","author":"Poynard","year":"2009","journal-title":"Hepatology"},{"issue":"23","key":"10.1002\/14651858.CD003617.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Bisceglie","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.24169","article-title":"Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon","volume":"53","author":"Bisceglie","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003617.pub2-BIB0008|cit8","first-page":"582a","article-title":"Is the platelet count determined by hepatic function or hypersplenism: Results of the HALT-C trial?","volume":"54","author":"Hoefs","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/j.gastro.2011.06.007","article-title":"Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial","volume":"141","author":"Hoefs","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","article-title":"Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C","volume":"3","author":"Lok","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0016-5085(99)70402-6","article-title":"A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia","volume":"117","author":"Shiffman","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0013|cit13","first-page":"A38","article-title":"PACIFIC: A phase III, randomized, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection","volume":"59 Suppl 2","author":"Tanwar","year":"2010","journal-title":"Gut"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003617.pub2-BIB0014|cit14","first-page":"710A","article-title":"PACIFIC: A phase III, randomized, multicenter, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection","volume":"52","author":"Tanwar","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MEG.0b013e3283513e69","article-title":"Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon \u03b1-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis","volume":"24","author":"Tanwar","year":"2012","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0016|cit16","first-page":"S197","article-title":"Retreatment with leukocite interferon of chronic hepatitis C patients non responders to recombinant interferon","volume":"26 Suppl 1","author":"Vaccaro","year":"1997","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/gut.52.5.701","article-title":"Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomized trial","volume":"52","author":"Adinolfi","year":"2003","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jhep.2011.05.034","article-title":"Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens","volume":"56","author":"Aghemo","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0377-4929.77330","article-title":"The sustained virologic response of nonresponder hepatitis C virus patients with retreatment","volume":"54","author":"Akham","year":"2011","journal-title":"Indian Journal of Pathology and Microbiology"},{"issue":"42","key":"10.1002\/14651858.CD003617.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.3748\/wjg.v12.i42.6861","article-title":"Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype relapsed after interferon monotherapy: a randomized controlled trial","volume":"12","author":"Alaimo","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD003617.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"137S","DOI":"10.1002\/hep.510260724","article-title":"Therapy of hepatitis C: re-treatment with alpha interferon","volume":"26","author":"Alberti","year":"1997","journal-title":"Hepatology"},{"issue":"Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0022|cit22","first-page":"416A","article-title":"Retreatment of relapsers with chronic hepatitis C: the effect of dose doubling and of host and viral factors","volume":"4","author":"Almasio","year":"1997","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1023\/A:1026625001168","article-title":"Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon","volume":"44","author":"Almasio","year":"1999","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0024|cit24","first-page":"S192","article-title":"Should patients with chronic hepatitis C who relapse after interferon (IFN) be retreated?","volume":"26 Suppl 1","author":"Fuschi","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0168-8278(99)80130-5","article-title":"Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial","volume":"30","author":"Andreone","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-8278(00)80775-8","article-title":"High dose of interferon plus ribavirin for 6 or 12 months in non responder patients with chronic hepatitis C: results of a randomized trial","volume":"32 Suppl 2","author":"Andreone","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02358369","article-title":"Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C","volume":"29","author":"Arase","year":"1994","journal-title":"Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s005350300026","article-title":"Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load","volume":"38","author":"Arase","year":"2003","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1386-6346(02)00327-3","article-title":"Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load","volume":"25","author":"Arase","year":"2003","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0030|cit30","first-page":"455","article-title":"Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C","volume":"133","author":"August-J\u00f6rg","year":"2003","journal-title":"Swiss Medical Weekly"},{"issue":"21","key":"10.1002\/14651858.CD003617.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3748\/wjg.v10.i21.3099","article-title":"Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis","volume":"10","author":"Azzaroli","year":"2004","journal-title":"World Journal of Gastroenterology: WJG"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(04)90457-6","article-title":"Retreatment with pegylated interferon alpha-2b and ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or interferon and ribavirin combination. A prospective randomized pilot study of two regimens: induction versus Peg","volume":"40 Suppl 1","author":"Bapin","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD003617.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1572-0241.1998.00702.x","article-title":"Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study","volume":"93","author":"Barbaro","year":"1998","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD003617.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/003655299750025426","article-title":"Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators","volume":"34","author":"Barbaro","year":"1999","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(99)00160-6","article-title":"Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial","volume":"107","author":"Barbaro","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003617.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0168-8278(98)80343-7","article-title":"Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy","volume":"28","author":"Bekkering","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/00365529950173087","article-title":"Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group","volume":"34","author":"Bell","year":"1999","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2893.1997.00142.x","article-title":"Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial","volume":"4","author":"Bellobuono","year":"1997","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD003617.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1478-3231.2007.01540.x","article-title":"Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alfa-2b in chronic hepatitis C non-responders","volume":"27","author":"Bergmann","year":"2007","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0041|cit41","first-page":"3216","article-title":"Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group","volume":"46","author":"Bernardinello","year":"1999","journal-title":"Hepato-Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1478-3231.2005.01239.x","article-title":"Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon alfa therapy","volume":"26","author":"B\u00f6cher","year":"2006","journal-title":"Liver International"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02208597","article-title":"High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial","volume":"41","author":"Bonkovsky","year":"1996","journal-title":"Digestive Disease and Sciences"},{"issue":"8","key":"10.1002\/14651858.CD003617.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1590-8658(00)80334-5","article-title":"High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon","volume":"32","author":"Bresci","year":"2000","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2893.2000.00212.x","article-title":"Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon","volume":"7","author":"Bresci","year":"2000","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0047|cit47","first-page":"13","article-title":"Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience","volume":"23 Suppl 2","author":"Brillanti","year":"1995","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1005479207106","article-title":"Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C","volume":"45","author":"Buti","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0049|cit49","first-page":"159","article-title":"The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon","volume":"14","author":"Cagnoni","year":"1999","journal-title":"Annali of Italiani di Medicina Interna"},{"issue":"8","key":"10.1002\/14651858.CD003617.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1478-3231.2007.01535.x","article-title":"Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C","volume":"27","author":"Carr","year":"2007","journal-title":"Liver International"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0051|cit51","first-page":"234","article-title":"Retreatment with human leukocyte interferon alpha of chronic hepatitis C, recurring after a first cycle with recombinant interferon (Letter)","volume":"30","author":"Carrara","year":"1998","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0168-8278(00)80169-5","article-title":"The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group","volume":"33","author":"Cavalletto","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"1128","key":"10.1002\/14651858.CD003617.pub2-BIB0053|cit53","first-page":"103","article-title":"Interferon-alpha2a\/ribavirin versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon","volume":"114","author":"Chapman","year":"2001","journal-title":"New Zealand Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1053\/gast.1997.v113.pm9352869","article-title":"Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C","volume":"113","author":"Chemello","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(03)80724-9","article-title":"Efficacy of pegylated interferon alfa-2b in combination with ribavirin in patients with chronic hepatitis C non-responders to a previous treatment","volume":"38 Suppl 2","author":"Chousterman","year":"2003","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0056|cit56","first-page":"239A","article-title":"Colchicine versus peg-intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. (Abstract)","volume":"4 Suppl 1","author":"Afdahl","year":"2004","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(08)60005-7","article-title":"Colchicine versus peg-interferon alfa 2b long term therapy: results of the 4 year COPILOT trial","volume":"48 Suppl 2","author":"Afdahl","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0058|cit58","first-page":"259","article-title":"The effects of long term PEG-Interferon therapy on the development of esophageal varices and variceal bleeding in patients with hepatitis C and advanced fibrosis: Final results from the Copilot trial (Abstract)","volume":"136 Suppl 1","author":"Cardenas","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2005.10.021","article-title":"Treatment with daily consensus interferon plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study","volume":"44","author":"Cornberg","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0060|cit60","first-page":"S225","article-title":"Interferon therapy for chronic hepatitis C is associated with sustained histological improvement in virological nonresponders (NR) and responders with relapse (RR) (EASL abstract)","volume":"26 Suppl 1","author":"Cotler","year":"1997","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD003617.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1572-0241.2000.02353.x","article-title":"Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone","volume":"95","author":"Cuccorese","year":"2000","journal-title":"American Journal of Gastroenerology"},{"issue":"21","key":"10.1002\/14651858.CD003617.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group","volume":"339","author":"Davis","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0063|cit63","first-page":"317A","article-title":"Long-term continuous recombinant interferon alfa-2b (Intron A) versus repeated 24-week cycles for disease suppression in IFN-relapsers with chronic hepatitis C (Abstract)","volume":"30","author":"Davis","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1365-2036.2007.03470.x","article-title":"Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alfa-2a in hepatitis C virus genotype 1 true non-responder patients","volume":"26","author":"Diago","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/jhep.2000.8700","article-title":"Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial","volume":"32","author":"Bisceglie","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/jhep.2001.22346","article-title":"Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon","volume":"33","author":"Bisceglie","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0168-8278(00)80282-2","article-title":"Combined retreatment of relapse of chronic hepatitis C with high-dose alfa-2-b interferon plus ribavirin for 6 or 12 months","volume":"33","author":"Marco","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0068|cit68","first-page":"691A","article-title":"Efficacy of daily consensus interferon and ribavirin compared to peg-interferon-2b and ribavirin in non-responders with chronic hepatitis C","volume":"42","author":"Dollinger","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003617.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2893.2000.00243.x","article-title":"Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone","volume":"7","author":"Enriquez","year":"2000","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0168-8278(02)80838-8","article-title":"Combination of interferon induction therapy and ribavirin in primary interferon non-responders infected with genotype 1 hepatitis C virus","volume":"36 Suppl 1","author":"Erdem","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"33","key":"10.1002\/14651858.CD003617.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.3748\/wjg.v12.i33.5293","article-title":"Triple antiviral therapy in HCV positive patients who failed prior combination therapy","volume":"12","author":"Fargion","year":"2006","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2006.10.016","article-title":"Effect of prolonged Interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial","volume":"5","author":"Fartoux","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2893.2003.00409.x","article-title":"Efficacy of prolonged 5 millions unit of interferon in combination with ribavirin for relapser patients with chronic hepatitis C","volume":"10","author":"Fattovich","year":"2003","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2893.2004.00538.x","article-title":"A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone","volume":"11","author":"Fattovich","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD003617.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"103S","DOI":"10.1007\/BF02087884","article-title":"Dose increase augments response rate to interferon-alpha in chronic hepatitis C","volume":"41","author":"Ferenci","year":"1996","journal-title":"Digestive Diseases and Sciences"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0076|cit76","first-page":"349A","article-title":"Multicenter randomized trial of 15 mcg Infergen administered daily vs. thrice weekly in patients with chronic hepatitis C who did not respond to interferon (IFN) therapy (abstract)","volume":"32","author":"Fong","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0399-8320(07)89432-2","article-title":"Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection","volume":"31","author":"Fontagnes","year":"2007","journal-title":"Gastroenterologie Clinique et Biologique"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2893.1997.00146.x","article-title":"Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial","volume":"4","author":"Gaeta","year":"1997","journal-title":"Journal of Viral Hepatitis"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD003617.pub2-BIB0079|cit79","first-page":"118","article-title":"Interferon-alpha retreatment in chronic hepatitis C","volume":"22","author":"Gerken","year":"1995","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2036.2004.02095.x","article-title":"Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation","volume":"20","author":"Getachew","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0081|cit81","first-page":"S123","article-title":"Usefulness of re-treatment with interferon (IFN) in relapsing and non-responder patients with chronic hepatitis C (Abstract)","volume":"18 Suppl 1","author":"Giudici-Cipriani","year":"1993","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0082|cit82","first-page":"573A","article-title":"Daily interferon to suppress HCV viremia among interferon non-responders (Abstract)","volume":"28","author":"Gross","year":"1998","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0083|cit83","first-page":"634A","article-title":"Interferon alpha 2b 5MU TIW, +\/- 4-week daily interferon induction, +\/- ribavirin, for re-treatment of interferon non-responders with chronic hepatitis C (Abstract)","volume":"30","author":"Gross","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2893.1999.00148.x","article-title":"Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years","volume":"6","author":"Guerret","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0085|cit85","first-page":"420A","article-title":"Daily administration of interferon-alpha for 1 month followed by a TIW standard regimen is associated with high response rates in chronic hepatitis C (Abstract)","volume":"26","author":"Hadziyannis","year":"1997","journal-title":"Hepatology"},{"issue":"36","key":"10.1002\/14651858.CD003617.pub2-BIB0086|cit86","first-page":"1642","article-title":"Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon non-responders","volume":"47","author":"Hasan","year":"2000","journal-title":"Hepato-Gastroenterology"},{"issue":"34","key":"10.1002\/14651858.CD003617.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.3748\/wjg.v11.i34.5342","article-title":"High-dose interferon alfa-2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon alfa monotherapy","volume":"11","author":"Hass","year":"2005","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.510270431","article-title":"Re-treatment of chronic hepatitis C with consensus interferon","volume":"27","author":"Heathcote","year":"1998","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.510300202","article-title":"Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon","volume":"30","author":"Heathcote","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/hep.510280533","article-title":"Early hepatitis C virus-RNA predict interferon treatment outcomes in chronic hepatitis C","volume":"28","author":"Lee","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003617.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0168-8278(05)80644-0","article-title":"Retreatment with interferon in chronic hepatitis C (Letter)","volume":"21","author":"Horiike","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1386-6346(02)00142-0","article-title":"A randomized clinical trial with natural IFN-alfa monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers","volume":"24","author":"Iino","year":"2002","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0168-8278(98)80244-4","article-title":"A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a\/2b genotype hepatitis C virus","volume":"28","author":"Ikeda","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD003617.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/10799900050151102","article-title":"Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta?","volume":"20","author":"Ikeda","year":"2000","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1600-0676.1997.tb00786.x","article-title":"Recombinant interferon-\u03b1-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study","volume":"17","author":"Imai","year":"1997","journal-title":"Liver"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004836-200012000-00006","article-title":"Retreatment with interferon for chronic hepatitis C after transient response","volume":"31","author":"Iyoda","year":"2000","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD003617.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/0003-4819-150-8-200904210-00007","article-title":"Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon \u03b12b. A randomized trial","volume":"150","author":"Jensen","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0168-8278(05)80336-8","article-title":"Retreatment with interferon in patients with chronic hepatitis C","volume":"21","author":"Kakumu","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1365-2893.2001.00274.x","article-title":"Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance","volume":"8","author":"Katayama","year":"2001","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0100|cit100","first-page":"113","article-title":"A preliminary study of retreatment of chronic hepatitis C with interferon","volume":"86","author":"Kishihara","year":"1995","journal-title":"Fukuoka Igaku Zasshi"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"A571","DOI":"10.1016\/S0016-5085(01)82839-0","article-title":"Daily vs. thrice weekly interferon in combination with ribavirin for patients with chronic hepatitis C infection: preliminary results of a multicenter randomized trial","volume":"120","author":"Kumar","year":"2001","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0102|cit102","first-page":"536A","article-title":"Evaluation of interferon (alpha)-2b for the treatment of relapsed hepatitis C","volume":"24","author":"Le","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0168-8278(01)80532-8","article-title":"High-daily induction dose of interferon in combination with ribavirin in chronic hepatitis C non responder patients: a randomised controlled trial","volume":"34","author":"Leroy","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0104|cit104","first-page":"1034","article-title":"Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group","volume":"24","author":"Lindsay","year":"1996","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2893.2005.00638.x","article-title":"Higher doses if peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study","volume":"12","author":"Lodato","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0106|cit106","first-page":"200","article-title":"Enhanced response to peginterferon alfa-2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study","volume":"42 Suppl 2","author":"Mangia","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.22061","article-title":"Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial","volume":"47","author":"Mangia","year":"2008","journal-title":"Hepatology"},{"issue":"8923","key":"10.1002\/14651858.CD003617.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0140-6736(94)92129-6","article-title":"Retreatment with interferon-alpha of chronic hepatitis C virus infection","volume":"344","author":"Marcellin","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0168-8278(00)80282-2","article-title":"Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months","volume":"33","author":"Marco","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/infdis\/166.5.1200","article-title":"Retreatment of chronic hepatitis C with interferon-alpha","volume":"166","author":"Marriott","year":"1992","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1007\/s10620-006-9192-3","article-title":"Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment","volume":"51","author":"Mathew","year":"2006","journal-title":"Digestive Diseases and Sciciences"},{"issue":"30","key":"10.1002\/14651858.CD003617.pub2-BIB0112|cit112","first-page":"1","article-title":"Improvement in quality of life measures in patients with refractory hepatitis C, responding to retreatment with pegylated interferon alfa-2b and ribavirin","volume":"4","author":"Mathew","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0113|cit113","first-page":"211","article-title":"Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone","volume":"31","author":"Milella","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1572-0241.2001.03692.x","article-title":"Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone","volume":"96","author":"Min","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0168-8278(03)80812-7","article-title":"Controlled study of interferon alpha-2b plus ribavirin in patients with chronic hepatitis C non-responders to interferon","volume":"38 Suppl 2","author":"Moreno-Otero","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0116|cit116","first-page":"596A","article-title":"Prospective, randomized and controlled study of the efficacy and tolerance of interferon alpha plus ribavirin in chronic hepatitis C non responders to prior interferon","volume":"34","author":"Moreno-Otero","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0117|cit117","first-page":"A1251","article-title":"Interferon therapy of HCV cirrhosis reduces the incidence of HCC, and decompensation, and significantly improves survival: a 5 year comparative trial","volume":"29","author":"Mura","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"Neuman Manuela G Katz Gadi G Patel A Izabell M Izabella Malkiewicz M Esguerra R HCV-RNA and inflammasome is modulated by PEGylated interferon (PEG-IFNalpha-2b) monotherapy in chronic hepatitis C patients Clinical Biochemistry 2010","DOI":"10.1016\/j.clinbiochem.2010.04.024"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0119|cit119","first-page":"214","article-title":"Peginterferon alfa-2a (40 kDa) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy as in naive patients: results from the BERNAR-1 trial","volume":"42 Suppl 2","author":"Nevens","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"8982","key":"10.1002\/14651858.CD003617.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","article-title":"Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis","volume":"346","author":"Nishiguchi","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","article-title":"Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis","volume":"357","author":"Nishiguchi","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.hepres.2003.09.005","article-title":"Efficacy of early retreatment with interferon \u03b2 for relapse in patients with genotype 1b chronic hepatitis C","volume":"28","author":"Nomura","year":"2004","journal-title":"Hepatology Research"},{"issue":"8912","key":"10.1002\/14651858.CD003617.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(94)92968-8","article-title":"Retreatment of chronic hepatitis C virus infection (Letter)","volume":"343","author":"Pardo","year":"1994","journal-title":"Lancet"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0124|cit124","first-page":"273A","article-title":"A comparison of three interferon alpha-2b regimens for retreatment (RTT) of patients with chronic hepatitis C with prior complete response followed by relapse: a controlled, randomized trial (AASLD abstract)","volume":"24","author":"Payen","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003617.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/hep.510280631","article-title":"Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc)","volume":"28","author":"Payen","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.510290135","article-title":"Recombinant interferon alfa-2b\/ribavirin combined therapy followed by low dose recombinant interferon alfa-2b in chronic hepatitis C interferon nonresponders","volume":"29","author":"Perasso","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0168-8278(97)80068-2","article-title":"Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C","volume":"26","author":"Picciotto","year":"1997","journal-title":"Journal of Hepatology"},{"issue":"17","key":"10.1002\/14651858.CD003617.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0025-7753(02)72483-4","article-title":"Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study","volume":"118","author":"Planas","year":"2002","journal-title":"Medicina Clinica"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.21595","article-title":"Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis","volume":"45","author":"Goodman","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(99)80157-3","article-title":"A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France","volume":"31","author":"Pol","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"311A","DOI":"10.1016\/S0270-9139(03)80362-2","article-title":"Treatment with peg-interferon alfa-2b in relapsers to standard interferon plus ribavirin in chronic hepatitis C: efficacy and safety results from a randomized multicentric french study","volume":"38","author":"Portal","year":"2003","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2893.1999.00170.x","article-title":"A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group","volume":"6","author":"Poynard","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2893.2003.00427.x","article-title":"Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in he retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial","volume":"10","author":"Poynard","year":"2003","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1590-8658(01)80073-6","article-title":"Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone","volume":"33","author":"Puoti","year":"2001","journal-title":"Digestive and Liver Disease"},{"issue":"8","key":"10.1002\/14651858.CD003617.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1872-034X.2012.00984.x","article-title":"Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials","volume":"42","author":"Qu","year":"2012","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/00365549409008609","article-title":"Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response","volume":"26","author":"Reichard","year":"1994","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003617.pub2-BIB0137|cit137","first-page":"994A","article-title":"Safety and efficacy of pegylated interferon lambda (PEG-LAMBDA) compared to pegylated interferon alfa-2A (PEG-alfa) in HCV-infected patients (G1\/2\/3) with compensated cirrhosis: emerge phase IIB efficacy and safety results through week 12","volume":"54","author":"Rodriguez-Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0138|cit138","first-page":"S149","article-title":"Interest of high dose of interferon in non-responder CHC patients","volume":"25 Suppl 1","author":"Rolachon","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD003617.pub2-BIB0139|cit139","first-page":"924","article-title":"Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial","volume":"21","author":"Rolachon","year":"1997","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0168-8278(12)61166-0","article-title":"Peginterferon alpha-2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha-2B in chronic Hepatitis C: Meta-analysis of randomized clinical trials (RCT)","volume":"56 Suppl 2","author":"Romero-Gomez","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0141|cit141","first-page":"S50","article-title":"Phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection","volume":"44 Suppl 2","author":"Rustgi","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1478-3231.1999.tb00049.x","article-title":"Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial","volume":"19","author":"Salmeron","year":"1999","journal-title":"Liver"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0168-8278(05)80411-8","article-title":"Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C","volume":"21","author":"Saracco","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jhep.2001.25636","article-title":"A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone","volume":"34","author":"Saracco","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1053\/jhep.2002.35442","article-title":"A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy","volume":"36","author":"Saracco","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2007.01.041","article-title":"SCH 503034, a novel hepatitis C virus protease inhibitors, plus pegilated interferon alfa-2b for genotype 1 nonresponders","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD003617.pub2-BIB0147|cit147","first-page":"505","article-title":"Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone","volume":"28","author":"Scotto","year":"1996","journal-title":"Italian Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD003617.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1023\/A:1026693901012","article-title":"Effectiveness of Leukocyte Interferon-alfa treatment in patients with chronic hepatitis C not responsive to recombinant Interferon","volume":"43","author":"Scotto","year":"1998","journal-title":"Digestive Diseases and Sciences"},{"issue":"10","key":"10.1002\/14651858.CD003617.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1111\/j.1572-0241.2000.02321.x","article-title":"Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group","volume":"95","author":"Shiffman","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1365-2036.2010.04427.x","article-title":"Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy","volume":"32","author":"Singal","year":"2010","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2005.02.023","article-title":"Pilot study of interferon gamma for chronic hepatitis C","volume":"43","author":"Soza","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0152|cit152","first-page":"125","article-title":"Comparative study concerning the efficacy of peg-IFN alfa-2a versus peg-IFN alfa-2b on the early virological response in patients with chronic viral C hepatitis","volume":"15","author":"Sporea","year":"2006","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1600-0676.2003.00838.x","article-title":"Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy","volume":"23","author":"Steindl-Munda","year":"2003","journal-title":"Liver International"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s005350170110","article-title":"Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to once-daily regimen","volume":"36","author":"Suzuki","year":"2001","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2893.2005.00549.x","article-title":"The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of na\u00efve and nonresponder chronic hepatitis C patients","volume":"12","author":"Raptopoulou","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2893.2003.00406.x","article-title":"A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1","volume":"10","author":"Tassopoulos","year":"2003","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.hepres.2004.07.002","article-title":"Prediction of treatment outcome with daily high-dose interferon alfa-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy","volume":"30","author":"Iino","year":"2004","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0158|cit158","first-page":"539","article-title":"Comparision of interferon alfa-2b and ribavirin (SCH18908) combination therapy and interferon alfa-2b monotherapy in chronic hepatitis C patients who have not responded or relapsed to previous interferon therapy: a double-blind comparative study to examine concomitant efficacy","volume":"4","author":"Toyoda","year":"2002","journal-title":"Journal of Clinical and Therapeutical Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003617.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/hep.510290616","article-title":"Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment","volume":"29","author":"Valla","year":"1999","journal-title":"Hepatology"},{"issue":"Pt 2","key":"10.1002\/14651858.CD003617.pub2-BIB0160|cit160","first-page":"415A","article-title":"Higher dose interferon does not increase end-of-treatment virological response in nonresponders to interferon therapy (AASLD abstract)","volume":"4","author":"Wartelle","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00365549309169665","article-title":"Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment","volume":"25","author":"Weiland","year":"1993","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"4S","key":"10.1002\/14651858.CD003617.pub2-BIB0162|cit162","first-page":"1174","article-title":"A randomized, comparative, multicenter study of consensus interferon (CIFN) with interferon alpha-2a in patients with chronic hepatitis C virus (HCV) infection (Abstract)","volume":"26","author":"Yao","year":"1997","journal-title":"Hepatology"},{"issue":"23","key":"10.1002\/14651858.CD003617.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2005.05.016","article-title":"International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C","volume":"43","author":"Zeuzem","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3904\/kjim.1992.7.1.13","article-title":"Interferon alpha therapy in patients with chronic type C hepatitis: changes of serum ALT, anti-HCV, & HCV-RNA","volume":"7","author":"Cho","year":"1992","journal-title":"Korean Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0166|cit166","first-page":"302","article-title":"Hepatocarcinoma in HCV compensated correlated liver cirrhosis: role of treatment with interferon","volume":"93","author":"Testino","year":"2002","journal-title":"Recenti Progressi in Medicina"},{"issue":"10","key":"10.1002\/14651858.CD003617.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jmv.20925","article-title":"Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection","volume":"79","author":"Arase","year":"2007","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gut.49.3.423","article-title":"The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection","volume":"49","author":"Barrett","year":"2001","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/gut.2003.020263","article-title":"Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications","volume":"53","author":"Benvegnu","year":"2004","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005527","article-title":"Ribavirin monotherapy for chronic hepatitis C","author":"Brok","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.510300329","article-title":"Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP)","volume":"30","author":"Camma","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","article-title":"Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach","volume":"34","author":"Camma","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hep.20030","article-title":"Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth","volume":"39","author":"Casiraghi","year":"2004","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.3748\/wjg.v12.i34.5532","article-title":"Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment","volume":"12","author":"Chavalitdhamrong","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/jhep.2001.20675","article-title":"Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials","volume":"33","author":"Cheng","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/j.1572-0241.2006.00669.x","article-title":"Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?","volume":"101","author":"Ciancio","year":"2006","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0180|cit180","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis http:\/\/ctu.dk\/tsa\/"},{"issue":"22","key":"10.1002\/14651858.CD003617.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group","volume":"321","author":"Davis","year":"1989","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods of combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD003617.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2036.2008.03620.x","article-title":"Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis","volume":"27","author":"Everson","year":"2008","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1002\/14651858.CD003617.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0189|cit189","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2012, Issue 5. Art. No.: LIVER"},{"issue":"11","key":"10.1002\/14651858.CD003617.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0191|cit191","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"5 Suppl1","key":"10.1002\/14651858.CD003617.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of Hepatitic C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2893.2005.00707.x","article-title":"Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma inpatients with hepatitis C virus-related cirrhosis","volume":"13","author":"Hung","year":"2006","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0194|cit194","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.24561","article-title":"Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care","volume":"54","author":"Innes","year":"2011","journal-title":"Hepatology"},{"issue":"25","key":"10.1002\/14651858.CD003617.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD003617.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0199|cit199","first-page":"49","article-title":"Chronic hepatitis: more quotes and misquotes","volume-title":"Current Hepatology","volume":"15","author":"Koretz","year":"1995"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(96)90379-7","article-title":"Interferon and hepatocellular carcinoma","volume":"347","author":"Koretz","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003617.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0203|cit203","first-page":"67","article-title":"Safety of combination interferon alfa-2b\/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients","volume":"19 Suppl 1","author":"Maddrey","year":"1999","journal-title":"Seminars in Liver Disease"},{"issue":"9286","key":"10.1002\/14651858.CD003617.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD003617.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","article-title":"Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy","volume":"127","author":"Marcellin","year":"1997","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1002\/14651858.CD003617.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003617.pub2-BIB0211|cit211","first-page":"1","article-title":"Management of Hepatitis C","volume":"15","author":"Anonymous","year":"1997","journal-title":"NIH Consensus Statement"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2036.2001.00979.x","article-title":"Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis","volume":"15","author":"Papatheodoridis","year":"2001","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD003617.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"9138","key":"10.1002\/14651858.CD003617.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"issue":"9401","key":"10.1002\/14651858.CD003617.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(03)15109-4","article-title":"Viral hepatitis C","volume":"362","author":"Poynard","year":"2003","journal-title":"Lancet"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003617.pub2-BIB0217|cit217","first-page":"711A","article-title":"Impact of PegIntron maintenance therapy on biomarkers (Fibro Test[FT]-ActiTest[AT]) in cirrhotic (METAVIOR F4) HCV prior nonresponders: results from the EPIC3 cirrhosis maintenance trial","volume":"50","author":"Poynard","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0218|cit218","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"5","key":"10.1002\/14651858.CD003617.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-132-2-200001180-00003","article-title":"45-year follow-up of hepatitis C virus infection in healthy young adults.\u00a0","volume":"132","author":"Seeff","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/jhep.2001.21905","article-title":"Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis: a National Heart, Lung, and Blood Institute Collaborative Study","volume":"33","author":"Seeff","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003617.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0224|cit224","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0225|cit225","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual forTrial Sequential Analysis (TSA) http:\/\/ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJM199909163411202","article-title":"Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening","volume":"341","author":"Vogt","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in a random-effects meta-analysis","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD003617.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/jhep.2000.8169","article-title":"Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study","volume":"32","author":"Wiese","year":"2000","journal-title":"Hepatology"},{"issue":"7644","key":"10.1002\/14651858.CD003617.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003617.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.1840360724","article-title":"Treatment of patients with hepatitis C and cirrhosis","volume":"36","author":"Wright","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003617.pub2-BIB0232|cit232","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003617.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T19:10:52Z","timestamp":1731870652000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003617.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":232,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003617.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985694.793472625","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717985694.793473975","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}